Abbott’s BurstDR stimulation shows benefits in treating chronic pain

Abbott has announced that its proprietary BurstDR stimulation technology has demonstrated a strong performance in the treatment of chronic pain in a new study.

Results from the SUNBURST study have confirmed the superiority of BurstDR stimulation over traditional tonic spinal cord stimulation for patients suffering from chronic pain.

Additionally, a further substudy analysis suggested the benefits of standardising BurstDR stimulation programming could further improve clinical outcomes and offer additional symptom improvement for these patients.

BurstDR differs from other forms of stimulation by using intermittent burst pulses to mimic the body's natural nerve impulse patterns. It is the only approved form of burst stimulation to have been evaluated in a large-scale, multicentre, randomised, controlled clinical trial.

Dr Allen Burton, medical director of neuromodulation at Abbott, said: "This sub-study shows that we can continue to maximise patient benefits with BurstDR stimulation and build upon the superior pain relief delivered by the therapy over traditional tonic spinal cord stimulation therapy."

Abbott is the only medical device manufacturer to offer radiofrequency ablation and spinal cord stimulation therapy solutions, including BurstDR technology and stimulation of the dorsal root ganglion, for the treatment of chronic pain.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.